Source: International Congress 2014 – Sarcoidosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Goljan Geremek, M. Bednarek, E. Puscinska, A. Nowinski, A. Kowalska, M. Czystowska, D. Korzybski, D. Górecka (Warsaw, Poland). Methotrexate (MTX) as a single agent for treating chronic, progressive sarcoidosis. Eur Respir J 2014; 44: Suppl. 58, 473

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary function changes during treatment with rituximab in patients with rheumatoid arthritis Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidone Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Benefit of steroid-free treatment compared to standard therapy (ST) in pulmonary sarcoidosis Source: International Congress 2014 – ILDs 5 Year: 2014 Reduction in disease progression with nintedanib in the INPULSIS™ trials Source: International Congress 2014 – Clinical trials in IPF Year: 2014 How many patients require corticosteroid treatment in sarcoidosis? – Preliminary study Source: International Congress 2014 – Sarcoidosis Year: 2014 Methotrexate as a single agent for the treatment of patients with progressive pulmonary sarcoidosis Source: International Congress 2015 – Sarcoidosis: clinical Year: 2015 Childhood diffuse parenchymal lung diseases: Diagnosis, treatment and outcome Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 The efficacy of cyclosporine A in patients with clinicoradiologically diagnosed idiopathic nonspecific interstitial pneumonia Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Pirfenidone therapy for patients with progressive idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Morality predictors in acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 6 Year: 2014 Rituximab for the treatment of chronic hypersensitivity pneumonitis Source: International Congress 2015 – Interstitial lung diseases I Year: 2015 Are there any predictors of MTX response in progressive pulmonary sarcoidosis? Source: International Congress 2015 – Acute and chronic lung diseases: good clinical practice Year: 2015 Early detection of subclinical interstitial lung disease in patients with rheumatoid arthritis and effect of methotrexate therapy Source: International Congress 2014 – ILDs 4 Year: 2014 Aetiological panorama in the diagnosis of interstitial lung diseases Source: International Congress 2014 – ILDs 5 Year: 2014 Sarcoidosis related to interferon and ribavirin treatment of hepatitis C – Analysis of four cases Source: International Congress 2014 – Sarcoidosis Year: 2014 Intraindividual response to treatment with pirfenidone in two independent European IPF cohorts Source: International Congress 2014 – ILDs 2 Year: 2014 Beneficial effect of azithromycin in children with diffuse parenchymal lung disease Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Does the BTNL2 genotype influence the course of disease in Danish sarcoidosis patients? Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014 Clinical features and prognosis of 108 patients with lymphangioleiomyomatosis Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014